Navigation Links
ARUP Laboratories Applauds FDA's Decision on the Value of KRAS-Mutation Testing in Colorectal Cancer
Date:8/4/2009

SALT LAKE CITY, Aug. 4 /PRNewswire/ -- ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, supports the U.S. Food and Drug Administration's (FDA) decision to put KRAS on the label of two targeted drugs, Vectibix (panitumumab) and Erbitux (cetuximab). On July 17, 2009, the FDA noted that, "retrospective analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Erbitux/Vectibix in patients whose tumors had KRAS mutations in codon 12 or 13," and that the use of the drugs is not recommended for the treatment of colorectal cancer patients with these mutations.

ARUP offers leading-edge KRAS mutation-detection testing in colon-cancer patients which can identify nearly all of the patients who will not benefit from taking either Vectibix or Erbitux. These drugs cost tens of thousands of dollars per course of therapy and simply running ARUP's KRAS mutation-detection test can potentially eliminate ineffective patient treatment and decrease health care expenses. ARUP's technical bulletin, "KRAS Mutation Detection in Colorectal Cancer; For Determining Mutational Status that Confers Resistance to Anti-EGFR Therapy," elaborates on this testing and can be found at www.aruplab.com.

"In the United States, colorectal cancer is the third most common form of cancer and individuals have a 6 percent lifetime risk of developing this disease," said Executive Vice President of Corporate Communications Ronald L. Weiss, MD, MBA. "Our goal is to help our clients improve patient care as well as reduce unnecessary expenditures by promoting the benefits of KRAS testing."

KRAS mutation-detection assays test colorectal cancer to determine whether a particular therapeutic strategy should be used by oncologists. Most colorectal cancer is caused by somatic mutations and is not hereditary. Mutations in the oncogene KRAS are seen in over 40 percent of sporadic colorectal cancers. While several laboratories in the United States offer this test, ARUP Laboratories' KRAS assay detects all 12 mutations at codons 12 and 13; another highly publicized assay on the market detects only seven.

KRAS mutation-detection testing is just one example of how ARUP Laboratories can partner with laboratories and hospitals to improve patient care and decrease overall health care costs by helping reduce over-, under-, and misuse of laboratory tests. To learn more about how ARUP Laboratories can help your laboratory, please visit www.aruplab.com/Education/OnlinePresentations/utilization_management.jsp.

About ARUP Laboratories

ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and an enterprise of the University of Utah and its Department of Pathology. With more than 2,600 employees, ARUP offers in excess of 2,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays, for patients nationwide. Rather than competing with its clients for physician office business, ARUP chooses instead to support clients' existing test menus by offering highly complex and unique tests, with accompanying consultative support, to enhance their abilities to provide local and regional laboratory services. ARUP's clients include more than half of the nation's university teaching hospitals and children's hospitals, as well as multihospital groups, major commercial laboratories, group purchasing organizations, military and government facilities, and major clinics. ARUP is a worldwide leader in innovative laboratory research and development, led by the efforts of the ARUP Institute for Clinical & Experimental Pathology(R). Further information on ARUP Laboratories can be found at www.aruplab.com.


'/>"/>
SOURCE ARUP Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Creighton Medical Laboratories First to Offer New Cancer Test
2. Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays
3. IBT Laboratories to Launch New Pneumococcal Antibody Avidity Test at AAAAI Meeting, Booth 729
4. Acanya(TM) Gel, a New Treatment for Moderate to Severe Acne, Launched by Coria Laboratories
5. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
6. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
7. Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
8. IBT Laboratories Expands its Menu of Tests for Immune Deficiency
9. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
10. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
11. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017 Transparency Market Research observes ... of 91.6% in the global capsule filler market in ... been leading the overall market for a significant time ... in handling sophisticated designs and manufacturing machines to manage ... research and development to deliver innovative products with new ...
(Date:1/24/2017)... Jan. 24, 2017   QR Pharma , ... developing novel therapies for the treatment of Alzheimer,s, ... appointment of four world-class key opinion leaders to ... join QR Pharma,s previous roster of impressive advisors ... to support the development of the breakthrough mechanism ...
(Date:1/24/2017)... -- The global  mammography market  is expected ... 2025, according to a new report by Grand View ... the rising initiatives by various governments and NGOs to ... breast tissue. Some significant organizations such as the National ... promoting the early diagnosis of mammary gland calcification, which ...
Breaking Medicine Technology:
(Date:1/24/2017)... , ... January 23, 2017 , ... ... coffee house-caliber protein and espresso drink, announced its CLICK® Coffee Protein Drink is ... CLICK® Coffee Protein Drink Mix has become popular among health-conscious consumers who love ...
(Date:1/24/2017)... ... January 23, 2017 , ... OSF Ventures, ... the world’s largest start-up platform headquartered in Silicon Valley that connects startups to ... Ventures recently signed a three-year agreement to be a corporate sponsor of Plug ...
(Date:1/24/2017)... , ... January 23, 2017 , ... The January 2017 ... a three-year outcome study on how outdoor behavioral healthcare (OBH) – also known as ... and interpersonal difficulties while experiencing an increased sense of purpose both during and after ...
(Date:1/24/2017)... (PRWEB) , ... January 23, 2017 , ... ... analyzed statistics from 140 Buzzies users who entered metrics into the product’s app. ... clinical data. The new data showed that within just 30 seconds of using ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... new plugin that allows sleep centers to automatically connect and initialize all their ... thin client browser plugin is quickly installed on first use and then monitors ...
Breaking Medicine News(10 mins):